Form 4: Altimmune Director Philip Hodges Acquires Stock Options

Director Philip Hodges acquired 34,900 stock options in Altimmune, Inc. on September 26, 2024, according to a Form 4 filing.

Summary

• Philip Hodges, a director at Altimmune, Inc., acquired 34,900 stock options on September 26, 2024.
• The options have an exercise price of $6.81.
• The options vest in equal monthly installments over 12 months following the grant date, contingent upon continued service.
• A Power of Attorney was executed on September 30, 2024, granting Vipin K. Garg and Andrew Shutterly the authority to act on behalf of Philip Hodges for SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates